Published in Physician Law Weekly, October 24th, 2007
These data were presented at the 45th annual meeting of the Infectious Disease Society of America (IDSA) in San Diego, California. Ceftobiprole is licensed from, and is being co-developed with, Basilea Pharmaceutica Ltd.
Staphylococcus aureus is the predominant Gram-positive+ bacteria associated with many infections,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly